Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 16;151:1181–1193. doi: 10.1016/j.ijbiomac.2019.10.162

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 8 — Overexpression of pIFITM1 inhibits PRV infection. A Immunoblotting analysis of whole cell extracts from PK15 cells stably expressing vector or pIFITM1-Flag with antibodies against Flag. Actin served as a loading control. B Cell proliferation assay of PK15 cells stably expressing vector or pIFITM1-Flag for 0–72 h. C Fluorescent microscopy and FACS analysis of PRV-GFP (MOI 0.01) proliferation in PK15 cells stably expressing vector or pIFITM1-Flag for 36 h. Data are shown as mean ± SD based on three independent experiments. ***P < 0.001 determined by a two-tailed Student’s t-test. D TCID₅₀ assay in PK15 cells stably expressing vector or pIFITM1-Flag infected with PRV-GFP (MOI 0.1) for 24 h. Data are shown as mean ± SD based on three independent experiments. **P < 0.01 determined by two-tailed Student’s t-test. E TCID₅₀ assay in PK15 cells stably expressing vector or pIFITM1-Flag infected with PRV-QXX (MOI 0.1 or 1) for 24 h. Data are shown as mean ± SD based on three independent experiments. **P < 0.01, ***P < 0.001 determined by a two-tailed Student’s t-test. F One-step growth curve of PRV-QXX (MOI 0.1) in K15 cells stably expressing vector or pIFITM1-Flag at 2, 4, 6, 8, 12 or 24 h post-infection. Viral titer was determined by TCID₅₀ assay. G Immunoblotting analysis of whole cell extracts from PK15 cells stably expressing vector or pIFITM1-Flag infected with PRV-QXX (MOI 0.1) for 24 h with antibodies against PRV gE and Flag. Actin served as a loading control. H RT-qPCR analysis of PRV gB and TK mRNA expression in K15 cells stably expressing vector or pIFITM1-Flag infected with PRV-QXX (MOI 0.1) for 24 h. Data are shown as mean ± SD based on three independent experiments. ***P < 0.001 determined by a two-tailed Student’s t-test. I RT-qPCR analysis of IFN-β, ISG15 and IL-1β mRNA expression in PK15 cells stably expressing vector or pIFITM1-Flag treated as in H. Data are shown as mean ± SD based on three independent experiments. **P < 0.01, ***P < 0.001 determined by a two-tailed Student’s t-test.